Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation

NCT04711226 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped No participants enrolled

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG: AT-1501

Sponsor

Anelixis Therapeutics, LLC